Interestingly, acquired resistance of CDK4/6 inhibitors is widely thought to function via activation of the upstream PI3K/AKT [24], which could be resensitized by targeting activated PI3K/mTOR signaling in CCA cells resistant to CDK4/6 [25]. The gene discussed is AKT1; the disease is cholangiocarcinoma.